FDA compliance office analyzing inspection and enforcement data to detect trends.
This article was originally published in The Tan Sheet
Executive Summary
FDA COMPLIANCE OFFICE ANALYZING INSPECTION AND ENFORCEMENT DATA to get a clearer picture of current trends and compliance trouble spots, FDA Division of Manufacturing & Product Quality Director Douglas Ellsworth explained at the National Association of Pharmaceutical Manufacturers annual meeting in Naples, Fla. on Jan 31. The analysis has not been completed for 1996, but Ellsworth said preliminary review of the data indicates that the GMP trouble spots "remain pretty much what they have been for some time": lab operations, validation issues and "in some areas of the bulk industry, adequate contamination control."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning